Article

CDK9 recruits HUWE1 E3 ligase to degrade RARα in a kinase independent manner and offers therapeutic opportunities for cutaneous T-cell lymphoma

2024-05-02

Abstract excerpt

<title>Abstract</title> <p>Cutaneous T-cell lymphoma (CTCL) is a highly heterogeneous non-Hodgkin lymphoma that originates from the skin and invades the systemic hematopoietic system. Current skin-directed or systemic treatment including chemotherapy, retinoid analogs, interferons, HDAC inhibitors and monoclonal antibodies yielded limited clinical responses with high incidence of side effects, emphasizing urgent...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8bbd1e0a-07ca-5b11-848b-7846f630ede8
DOI: 10.21203/rs.3.rs-4259549/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CDK9 recruits HUWE1 E3 ligase to degrade RARα in a kinase independent manner and offers therapeutic opportunities for cutaneous T-cell lymphomaDOI 10.21203/rs.3.rs-4259549/v1Read

Single Cell Resolution Tracking of Cutaneous T-Cell Lymphoma Reveals Clonal Evolution in Disease ProgressionSemantic proximity Read

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developmentsSemantic proximity Read

CDK9 degradation Inhibits Gastroesophageal Cancer growth and Overcomes Radiation Resistance by Increasing Chromatin Accessibility and Downregulating YAP1/TEAD signalingSemantic proximity Read

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphomaSemantic proximity Read

Addressing Transcriptional Dysregulation in Cancer through CDK9 InhibitionSemantic proximity Read

CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitorsSemantic proximity Read

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast CancerSemantic proximity Read

Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma.Semantic proximity Read

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaSemantic proximity Read

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.Semantic proximity Read

CDK9: A key player in cancer and other diseasesSemantic proximity Read